Literature DB >> 10365303

Common orthopaedic problems in haemophilia.

E C Rodriguez-Merchan1.   

Abstract

The most important fact in patients with haemophilia is the avoidance of recurrent haemarthroses by means of haematological prophylaxis. Unfortunately this is not currently possible in the majority of countries around the world. When only on-demand haematological treatment is available, frequent evaluations are necessary for the early diagnosis and treatment of intra-articular bleeding episodes. The typical outcome of these patients is towards the development of chronic synovitis, and later on to haemophilic arthropathy, if the state of synovitis is not promptly and adequately controlled. Once arthropathy develops the functional prognosis is poor, although haemophilic patients use to tolerate very well their tremendous joints destructions. Treatment of these patients should be performed in a comprehensive basis within a multidisciplinary haemophilia unit.

Entities:  

Mesh:

Year:  1999        PMID: 10365303     DOI: 10.1046/j.1365-2516.1999.0050s1053.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

1.  Risk factors for postoperative complications of orthopedic surgery in patients with hemophilia: Second report.

Authors:  Jun Hirose; Hideyuki Takedani; Masanori Nojima; Tomohiko Koibuchi
Journal:  J Orthop       Date:  2018-05-07

2.  Functional disability in children with hemophilic arthropathy.

Authors:  Eda Gurcay; Emel Eksioglu; Ustun Ezer; Reyhan Tuncay; Aytul Cakci
Journal:  Rheumatol Int       Date:  2006-02-17       Impact factor: 2.631

Review 3.  Radiosynovectomy in rheumatic diseases.

Authors:  Jarosław B Ćwikła; Piotr Żbikowski; Brygida Kwiatkowska; John R Buscombe; Iwona Sudoł-Szopińska
Journal:  J Ultrason       Date:  2014-09-30

4.  Health-Related Quality of Life and Association With Arthropathy in Greek Patients with Hemophilia.

Authors:  Agoritsa Varaklioti; Nick Kontodimopoulos; Dimitris Niakas; Anna Kouramba; Olga Katsarou
Journal:  Clin Appl Thromb Hemost       Date:  2017-10-09       Impact factor: 2.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.